Blauvelt, A. .; Rich, P.; Sofen, H.; Lambert, J.; Merola, J.; Lebwohl, M.; Hippeli, L.; Kisa, R.; Banerjee, S.; Kimball, A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2022, 6, s41.